GLOBAL MARKETS ROUNDUP* Nifty futures on the Singapore Exchange are down 0.66percent, while the MSCI-Asia Pacific excluding Japan index was lower 0.95 percent.* Asian stocks languished in early trade on Thursday and thedollar firmed, after minutes of the Federal Reserve's latestpolicy meeting showed it remained on track to taper its stimulusdespite a recent spate of downbeat U.S. economic data. * U.S. stocks slid on Wednesday in a late selloff after minutesof the U.S. Federal Reserve's latest policy-setting meetingindicated that the central bank will keep trimming itsbond-buying stimulus unless there is a significant economicsurprise. KEY FACTORS/EVENTS TO WATCH* Reserve Bank of India to release weekly money supply data* U.S. CPI data* Bank of Japan meet minutes INDIAN STOCKS TO WATCHFor additional press items double click NOTE: Reuters has not verified third-party stories and does notvouch for their accuracy. U.S. energy secretary to visit India from March 10-12 - India's Bajaj to deepen Kawasaki, KTM partnerships to liftexports - FTSE suspends Essar Energy's minimum free float deadlinepending bid Telecom M&A policy likely to be presented in cabinet by Feb27 (Mint) (http://link.reuters.com/pyj96v) Maruti Suzuki India cuts prices by 8,500 rupees to 31,000rupees - Mahindra & Mahindra to cut prices across vehicle range withimmediate effect - Vodafone blames India for collapse of $2 bln tax disputetalks - ITC planning to foray into food business with dairy,beverages (Economic Times) (http://link.reuters.com/qyj96v) Government proposes relaxation of FDI norms in construction(Economic Times) (http://link.reuters.com/ryj96v) Modi to bat for rejig of welfare schemes (Business Standard)(http://link.reuters.com/syj96v) RIL to raise over $1 bln through export credit (BusinessStandard) (http://link.reuters.com/tyj96v) Infosys executive exits necessary, will continue: NarayanaMurthy (Mint) (http://link.reuters.com/vyj96v) UBI blames Infy tool for failing to detect NPAs (BusinessStandard) (http://link.reuters.com/wyj96v) (Compiled by Dipika Lalwani)
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.
Read more